Watermark
Go to Asia edition

Alizyme

  • 22 Apr 2005

Nomura is leading a £30.5m capital increase for Alizyme, which develops treatments for obesity and gastrointestinal complaints.

Shareholders will be offered 30.5m shares in the company, equal to about 21% of its share capital, on a four-for-19 basis at a subscription price of 100p, a ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial
Log in

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Bond Comments

All International Bonds

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 JPMorgan 189,125.64 835 8.18%
2 Citi 178,481.94 729 7.72%
3 Bank of America Merrill Lynch 148,726.70 609 6.43%
4 Barclays 141,595.74 562 6.12%
5 HSBC 118,154.11 612 5.11%

Bookrunners of All Syndicated Loans EMEA

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 Credit Agricole CIB 21,626.10 74 8.29%
2 BNP Paribas 19,199.68 81 7.36%
3 Bank of America Merrill Lynch 17,431.25 46 6.69%
4 Deutsche Bank 12,826.80 46 4.92%
5 SG Corporate & Investment Banking 12,165.84 59 4.67%

Bookrunners of all EMEA ECM Issuance

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 Morgan Stanley 6,404.49 28 10.39%
2 JPMorgan 5,765.60 34 9.35%
3 Goldman Sachs 5,589.53 27 9.07%
4 UBS 4,134.32 20 6.71%
5 Citi 4,039.74 28 6.55%